Katoo Manon Muylle
Katoo Manon Muylle has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Pieter Cornu
Research Centre for Digital Medicine, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium
8 shared publications - Sven Van Laere
Department of Radiotherapy, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090 Brussels, Belgium
3 shared publications Alain G. Dupont
Department of Pharmaceutical and Pharmacological Sciences (FARM), Research Group Clinical Pharmacology & Clinical Pharmacy (KFAR), Vrije Universiteit Brussel, Laarbeeklaan 103, Brussels, Belgium
2 shared publications- Alain G. Dupont
Research Centre for Digital Medicine, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel (VUB), Brussels, Belgium
2 shared publications - Alain Gilbert Dupont
Department of Pharmaceutical and Pharmacological Sciences (FARM), Research Group Clinical Pharmacology & Clinical Pharmacy (KFAR), Vrije Universiteit Brussel, Brussels, Belgium
2 shared publications - Annelies Verbiest
Department of Medical Oncology, Multidisciplinary Oncology Center Antwerp, University Hospital Antwerp, Edegem, Belgium
2 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Springer Nature in npj Primary Care Respiratory Medicine
Incident COPD in Belgian primary care: Exacerbation profiles, treatment patterns and opportunities to advance guideline concordant care
- 17 September 2026
- Published by Springer Nature in npj Primary Care Respiratory Medicine
Open AccessIncident COPD in Belgian primary care: Exacerbation profiles, treatment patterns and opportunities to advance guideline concordant care
- Open Access
- 19 January 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 11, 100668
Real-world demographics, clinical characteristics, and testing and treatment patterns in patients with non-small-cell lung cancer and extensive-stage small-cell lung cancer in Belgium: the AIBED study
- 19 January 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 11, 100668
Open AccessReal-world demographics, clinical characteristics, and testing and treatment patterns in patients with non-small-cell lung cancer and extensive-stage small-cell lung cancer in Belgium: the AIBED study
- Open Access
- 8 January 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (2) , 95-105
Real-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium
Data about the clinical management of patients with ovarian cancer (OC) in real-world settings are scarce. This study documents baseline characteristics, treatments, and clinical outcomes in a real-world population of women with newly diagnosed advanced-stage OC in Belgium. This observational study, conducted at four hospitals in Belgium, retrospectively enrolled 120 women with FIGO (International Federation of Gynecology and Obstetrics classification) stage III or IV high-grade serous or endometrioid OC diagnosed between 2007 and 2018. Treatment outcomes, response to therapy, and patient survival were followed up until 20 months after diagnosis. Of 113 patients with a clinical response assessment, 49.6% were diagnosed with a stage IV disease, 53.1% underwent interval debulking surgery, 98.2% received any type of chemotherapy, and 35.4% received bevacizumab. Deleterious mutations in breast cancer susceptibility genes (BRCA1/BRCA2) were detected in 12/84 (14.3%) patients. After primary or interval debulking surgery, 50.0% and 60.0% of stage III, and 66.7% and 80.0% of stage IV patients had no visible residual disease, respectively. Following chemotherapy, 59.3% of patients had complete clinical response and/or no visible residual disease. Until month 20 of follow-up, 37.2% of patients were disease-free. Until 2018, surgical resection followed by first-line chemotherapy and bevacizumab use comprised the cornerstone therapy for newly diagnosed FIGO stage IV OC in Belgium. Clinical response and progression-free survival rates were relatively high. The patients' BRCA1/BRCA2 status was insufficiently characterized, likely reflecting the lack of perceived relevance of BRCA1/BRCA2 mutations for OC treatment before adoption of targeted therapies in clinical practice.
- 8 January 2026
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 81 (2) , 95-105
Open AccessReal-life data on clinical characteristics, treatments and outcomes of patients with newly diagnosed advanced-stage ovarian cancer: an observational study from Belgium
Data about the clinical management of patients with ovarian cancer (OC) in real-world settings are scarce. This study documents baseline characteristics, treatments, and clinical outcomes in a real-world population of women with newly diagnosed advanced-stage OC in Belgium. This observational study, conducted at four hospitals in Belgium, retrospectively enrolled 120 women with FIGO (International Federation of Gynecology and Obstetrics classification) stage III or IV high-grade serous or endometrioid OC diagnosed between 2007 and 2018. Treatment outcomes, response to therapy, and patient survival were followed up until 20 months after diagnosis. Of 113 patients with a clinical response assessment, 49.6% were diagnosed with a stage IV disease, 53.1% underwent interval debulking surgery, 98.2% received any type of chemotherapy, and 35.4% received bevacizumab. Deleterious mutations in breast cancer susceptibility genes (BRCA1/BRCA2) were detected in 12/84 (14.3%) patients. After primary or interval debulking surgery, 50.0% and 60.0% of stage III, and 66.7% and 80.0% of stage IV patients had no visible residual disease, respectively. Following chemotherapy, 59.3% of patients had complete clinical response and/or no visible residual disease. Until month 20 of follow-up, 37.2% of patients were disease-free. Until 2018, surgical resection followed by first-line chemotherapy and bevacizumab use comprised the cornerstone therapy for newly diagnosed FIGO stage IV OC in Belgium. Clinical response and progression-free survival rates were relatively high. The patients' BRCA1/BRCA2 status was insufficiently characterized, likely reflecting the lack of perceived relevance of BRCA1/BRCA2 mutations for OC treatment before adoption of targeted therapies in clinical practice.
- Open Access
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500159
Leveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study
PURPOSE: Chronic lymphocytic leukemia (CLL) treatment paradigms have evolved significantly, yet real-world evidence (RWE) on guideline implementation and patient characteristics remains limited. MATERIALS AND METHODS: This multicenter retrospective study leveraged artificial intelligence (AI) to analyze structured and unstructured data from four Belgian hospitals (January 1, 2018-October 31, 2021). Structured data including diagnosis codes, laboratory results, treatment records, and national registries were standardized using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Unstructured clinical notes and reports were processed using a transformer-based natural language processing (NLP) pipeline. We examined clinical characteristics, diagnostic testing, and treatment patterns among patients with newly diagnosed CLL. RESULTS: Of 22 variable groups analyzed, 50.0% was derived from structured data only, 36.4% from unstructured data only (NLP-extracted), and 13.6% from mixed sources. Five hundred eighty-six patients with CLL were identified, with a median age of 74 years. One hundred seventy-four patients (29.7%) initiated first-line (1L) treatment, and 41 progressed to second-line treatment. Of 1L treated patients, 68.4% had at least one prespecified comorbidity, including 12.1% with significant cardiovascular disease. TP53 /del17p testing was documented in 34.3% of patients before 1L treatment, with aberrations detected in 42.8%. Bruton's tyrosine kinase inhibitors (BTKi; 35.6%) were the most common 1L treatment, followed by chemoimmunotherapy (CIT; 25.9%). CIT use declined (30.6% to 17.5%), whereas BTKi use remained stable (34.2% to 38.1%) between 2018 and 2021. CONCLUSION: This AI-augmented study demonstrates the feasibility and scalability of combining NLP-derived insights with OMOP-standardized structured data to generate reproducible RWE in hematology. Our results highlight an elderly CLL population with significant comorbidities and a shift toward targeted therapies. While treatment patterns aligned with guidelines, data quality depended on source documentation accessibility. Improved integration of molecular testing into electronic health records is essential for enhancing clinical decision making, patient outcomes, and future research.
- 1 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 10 (1) , e2500159
Open AccessLeveraging Digital Technology and Artificial Intelligence to Describe the Real-World Belgian Chronic Lymphocytic Leukemia Patient Population: The BE-CLLEAR Study
PURPOSE: Chronic lymphocytic leukemia (CLL) treatment paradigms have evolved significantly, yet real-world evidence (RWE) on guideline implementation and patient characteristics remains limited. MATERIALS AND METHODS: This multicenter retrospective study leveraged artificial intelligence (AI) to analyze structured and unstructured data from four Belgian hospitals (January 1, 2018-October 31, 2021). Structured data including diagnosis codes, laboratory results, treatment records, and national registries were standardized using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Unstructured clinical notes and reports were processed using a transformer-based natural language processing (NLP) pipeline. We examined clinical characteristics, diagnostic testing, and treatment patterns among patients with newly diagnosed CLL. RESULTS: Of 22 variable groups analyzed, 50.0% was derived from structured data only, 36.4% from unstructured data only (NLP-extracted), and 13.6% from mixed sources. Five hundred eighty-six patients with CLL were identified, with a median age of 74 years. One hundred seventy-four patients (29.7%) initiated first-line (1L) treatment, and 41 progressed to second-line treatment. Of 1L treated patients, 68.4% had at least one prespecified comorbidity, including 12.1% with significant cardiovascular disease. TP53 /del17p testing was documented in 34.3% of patients before 1L treatment, with aberrations detected in 42.8%. Bruton's tyrosine kinase inhibitors (BTKi; 35.6%) were the most common 1L treatment, followed by chemoimmunotherapy (CIT; 25.9%). CIT use declined (30.6% to 17.5%), whereas BTKi use remained stable (34.2% to 38.1%) between 2018 and 2021. CONCLUSION: This AI-augmented study demonstrates the feasibility and scalability of combining NLP-derived insights with OMOP-standardized structured data to generate reproducible RWE in hematology. Our results highlight an elderly CLL population with significant comorbidities and a shift toward targeted therapies. While treatment patterns aligned with guidelines, data quality depended on source documentation accessibility. Improved integration of molecular testing into electronic health records is essential for enhancing clinical decision making, patient outcomes, and future research.
- Open Access
- 7 January 2024
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 12 (1) , 1-2
Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We There Yet? A Response to the Recent Commentaries
- 7 January 2024
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 12 (1) , 1-2
Open AccessClinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We There Yet? A Response to the Recent Commentaries
- 26 December 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (2) , 519-526.e3
Usability of Graphical User Interfaces With Semiautomatic Delabeling Feature to Improve Drug Allergy Documentation
- 26 December 2022
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 11 (2) , 519-526.e3
Usability of Graphical User Interfaces With Semiautomatic Delabeling Feature to Improve Drug Allergy Documentation
- 23 November 2022
- Published by Springer Nature in Journal of Medical Systems
- Vol. 46 (12) , 1-10
Machine Learning Techniques Outperform Conventional Statistical Methods in the Prediction of High Risk QTc Prolongation Related to a Drug-Drug Interaction
In clinical practice, many drug therapies are associated with prolongation of the QT interval. In literature, estimation of the risk of prescribing drug-induced QT prolongation is mainly executed by means of logistic regression; only one paper reported the use of machine learning techniques. In this paper, we compare the performance of both techniques on the same dataset. High risk for QT prolongation was defined as having a corrected QT interval (QTc) ≥ 450 ms or ≥ 470 ms for respectively male and female patients. Both conventional statistical methods (CSM) and machine learning techniques (MLT) were used. All algorithms were validated internally and with a hold-out dataset of respectively 512 and 102 drug-drug interactions with possible drug-induced QTc prolongation. MLT outperformed the best CSM in both internal and hold-out validation. Random forest and Adaboost classification performed best in the hold-out set with an equal harmonic mean of sensitivity and specificity (HMSS) of 81.2% and an equal accuracy of 82.4% in a hold-out dataset. Sensitivity and specificity were both high (respectively 75.6% and 87.7%). The most important features were baseline QTc value, C-reactive protein level, heart rate at baseline, age, calcium level, renal function, serum potassium level and the atrial fibrillation status. All CSM performed similarly with HMSS varying between 60.3% and 66.3%. The overall performance of logistic regression was 62.0%. MLT (bagging and boosting) outperform CSM in predicting drug-induced QTc prolongation. Additionally, 19.2% was gained in terms of performance by random forest and Adaboost classification compared to logistic regression (the most used technique in literature in estimating the risk for QTc prolongation). Future research should focus on testing the classification on fully external data, further exploring potential of other (new) machine and deep learning models and on generating data pipelines to automatically feed the data to the classifier used.
- 23 November 2022
- Published by Springer Nature in Journal of Medical Systems
- Vol. 46 (12) , 1-10
Machine Learning Techniques Outperform Conventional Statistical Methods in the Prediction of High Risk QTc Prolongation Related to a Drug-Drug Interaction
In clinical practice, many drug therapies are associated with prolongation of the QT interval. In literature, estimation of the risk of prescribing drug-induced QT prolongation is mainly executed by means of logistic regression; only one paper reported the use of machine learning techniques. In this paper, we compare the performance of both techniques on the same dataset. High risk for QT prolongation was defined as having a corrected QT interval (QTc) ≥ 450 ms or ≥ 470 ms for respectively male and female patients. Both conventional statistical methods (CSM) and machine learning techniques (MLT) were used. All algorithms were validated internally and with a hold-out dataset of respectively 512 and 102 drug-drug interactions with possible drug-induced QTc prolongation. MLT outperformed the best CSM in both internal and hold-out validation. Random forest and Adaboost classification performed best in the hold-out set with an equal harmonic mean of sensitivity and specificity (HMSS) of 81.2% and an equal accuracy of 82.4% in a hold-out dataset. Sensitivity and specificity were both high (respectively 75.6% and 87.7%). The most important features were baseline QTc value, C-reactive protein level, heart rate at baseline, age, calcium level, renal function, serum potassium level and the atrial fibrillation status. All CSM performed similarly with HMSS varying between 60.3% and 66.3%. The overall performance of logistic regression was 62.0%. MLT (bagging and boosting) outperform CSM in predicting drug-induced QTc prolongation. Additionally, 19.2% was gained in terms of performance by random forest and Adaboost classification compared to logistic regression (the most used technique in literature in estimating the risk for QTc prolongation). Future research should focus on testing the classification on fully external data, further exploring potential of other (new) machine and deep learning models and on generating data pipelines to automatically feed the data to the classifier used.
- 22 November 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (4) , 1374-1385
Added value of patient‐ and drug‐related factors to stratify drug‐drug interaction alerts for risk of QT prolongation: Development and validation of a risk prediction model
Aims: Many clinical decision support systems trigger warning alerts for drug‐drug interactions potentially leading to QT prolongation and torsades de pointes (QT‐DDIs). Unfortunately, there is overalerting and underalerting because stratification is only based on a fixed QT‐DDI severity level. We aimed to improve QT‐DDI alerting by developing and validating a risk prediction model considering patient‐ and drug‐related factors.Methods: We fitted 31 predictor candidates to a stepwise linear regression for 1000 bootstrap samples and selected the predictors present in 95% of the 1000 models. A final linear regression model with those variables was fitted on the original development sample (350 QT‐DDIs). This model was validated on an external dataset (143 QT‐DDIs). Both true QTc and predicted QTc were stratified into three risk levels (low, moderate and high). Stratification of QT‐DDIs could be appropriate (predicted risk = true risk), acceptable (one risk level difference) or inappropriate (two risk levels difference).Results: The final model included 11 predictors with the three most important being use of antiarrhythmics, age and baseline QTc. Comparing current practice to the prediction model, appropriate stratification increased significantly from 37% to 54% appropriate QT‐DDIs (increase of 17.5% on average [95% CI +5.4% to +29.6%], padj = 0.006) and inappropriate stratification decreased significantly from 13% to 1% inappropriate QT‐DDIs (decrease of 11.2% on average [95% CI −17.7% to −4.7%], padj ≤ 0.001).Conclusion: The prediction model including patient‐ and drug‐related factors outperformed QT alerting based on QT‐DDI severity alone and therefore is a promising strategy to improve DDI alerting.
- 22 November 2022
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (4) , 1374-1385
Added value of patient‐ and drug‐related factors to stratify drug‐drug interaction alerts for risk of QT prolongation: Development and validation of a risk prediction model
Aims: Many clinical decision support systems trigger warning alerts for drug‐drug interactions potentially leading to QT prolongation and torsades de pointes (QT‐DDIs). Unfortunately, there is overalerting and underalerting because stratification is only based on a fixed QT‐DDI severity level. We aimed to improve QT‐DDI alerting by developing and validating a risk prediction model considering patient‐ and drug‐related factors.Methods: We fitted 31 predictor candidates to a stepwise linear regression for 1000 bootstrap samples and selected the predictors present in 95% of the 1000 models. A final linear regression model with those variables was fitted on the original development sample (350 QT‐DDIs). This model was validated on an external dataset (143 QT‐DDIs). Both true QTc and predicted QTc were stratified into three risk levels (low, moderate and high). Stratification of QT‐DDIs could be appropriate (predicted risk = true risk), acceptable (one risk level difference) or inappropriate (two risk levels difference).Results: The final model included 11 predictors with the three most important being use of antiarrhythmics, age and baseline QTc. Comparing current practice to the prediction model, appropriate stratification increased significantly from 37% to 54% appropriate QT‐DDIs (increase of 17.5% on average [95% CI +5.4% to +29.6%], padj = 0.006) and inappropriate stratification decreased significantly from 13% to 1% inappropriate QT‐DDIs (decrease of 11.2% on average [95% CI −17.7% to −4.7%], padj ≤ 0.001).Conclusion: The prediction model including patient‐ and drug‐related factors outperformed QT alerting based on QT‐DDI severity alone and therefore is a promising strategy to improve DDI alerting.
- Open Access
- 6 April 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (4) , e12141
Physicians' needs for drug allergy documentation in electronic health records and allergy alert systems: Results of an end user's survey
- 6 April 2022
- Published by Wiley in Clinical and Translational Allergy
- Vol. 12 (4) , e12141
Open AccessPhysicians' needs for drug allergy documentation in electronic health records and allergy alert systems: Results of an end user's survey
- Open Access
- 18 October 2021
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 11 (12) , 3159-3163
Clinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? - A Viewpoint Paper
- 18 October 2021
- Published by Maad Rayan Publishing Company in International Journal of Health Policy and Management
- Vol. 11 (12) , 3159-3163
Open AccessClinical Decision Support and New Regulatory Frameworks for Medical Devices: Are We Ready for It? - A Viewpoint Paper